Table 1.
Demographic and Clinical characteristics of adults receiving repeat kidney transplants in the United States (N = 12,944) from 2003 through 2013.
| Variables | Antithymocyte globulin | Alemtuzumab |
Basiliximab |
p Value |
|---|---|---|---|---|
| N = 9120 | N = 1687 | N = 2137 | ||
| Donor type: | <.001 | |||
| Expanded criteria deceased | 475 (5.21) | 116 (6.88) | 106 (4.96) | |
| Standard criteria deceased | 6008 (65.88) | 996 (59.04) | 1103 (51.61) | |
| Living | 2637 (28.91) | 575 (34.08) | 928 (43.43) | |
| Donor race: | <.001 | |||
| Black | 1145 (12.55) | 206 (12.21) | 191 (8.94) | |
| Others | 7975 (87.45) | 1481 (87.79) | 1946 (91.06) | |
| Recipient age, years: | ||||
| Mean (SD) | 44.36 (12.59) | 44.69 (13.07) | 46.15 (13.43) | <.001 |
| Range | 18–78 | 18–79 | 18–88 | — |
| Recipient race: | <.001 | |||
| Black | 2077 (22.77) | 389 (23.06) | 314 (14.69) | |
| Others | 7043 (77.23) | 1298 (76.94) | 1823 (85.31) | |
| Primary kidney disease: | ||||
| Glomerulonephritis | 3417 (37.47) | 632 (37.46) | 776 (36.31) | 0.60 |
| Pretransplant dialysis: | <.001 | |||
| 1 day–1 year | 1392 (15.26) | 291 (17.25) | 462 (21.62) | |
| >1 year | 6515 (71.44) | 1154 (68.41) | 1217 (56.95) | |
| No dialysis | 1213 (13.30) | 242 (14.34) | 458 (21.43) | |
| Pretransplant PRA: | <.001 | |||
| PRA 0–20% | 2408 (26.40) | 446 (26.44) | 981 (45.91) | |
| PRA > 20% | 6712 (73.60) | 1241 (73.56) | 1156 (54.09) | |
| HLA mismatch | <.001 | |||
| 0–3 | 4215 (46.31) | 801 (47.57) | 1116 (52.30) | |
| More than 3 | 4886 (53.69) | 883 (52.43) | 1018 (47.70) | |
| Transplant year: | <.001 | |||
| 2003–2008 | 4344 (47.63) | 656 (38.89) | 1299 (60.79) | |
| 2009–2013 | 4776 (52.37) | 1031 (61.11) | 838 (39.21) | |
| Steroids included in maintenance Immunosuppression regimen: | <.001 | |||
| No | 1468 (16.10) | 817 (48.43) | 232 (10.86) | |
| Yes | 7652 (83.90) | 870 (51.57) | 1905 (89.14) |